AIMS: To evaluate our proposed multivariate approach to identify patients who will develop sight-threatening diabetic retinopathy (STDR) within a 1-year screen interval, and explore the impact of simple stratification rules on prediction. MATERIALS AND METHODS: A 7-year dataset (2009-2016) from people with diabetes (PWD) was analysed using a novel multivariate longitudinal discriminant approach. Level of diabetic retinopathy, assessed from routine digital screening photographs of both eyes, was jointly modelled using clinical data collected over time. Simple stratification rules based on retinopathy level were also applied and compared with the multivariate discriminant approach. RESULTS: Data from 13 103 PWD (49 520 screening episodes) were analysed. The multivariate approach accurately predicted whether patients developed STDR or not within 1 year from the time of prediction in 84.0% of patients (95% confidence interval [CI] 80.4-89.7), compared with 56.7% (95% CI 55.5-58.0) and 79.7% (95% CI 78.8-80.6) achieved by the two stratification rules. While the stratification rules detected up to 95.2% (95% CI 92.2-97.6) of the STDR cases (sensitivity) only 55.6% (95% CI 54.5-56.7) of patients who did not develop STDR were correctly identified (specificity), compared with 85.4% (95% CI 80.4-89.7%) and 84.0% (95% CI 80.7-87.6%), respectively, achieved by the multivariate risk model. CONCLUSIONS: Accurate prediction of progression to STDR in PWD can be achieved using a multivariate risk model whilst also maintaining desirable specificity. While simple stratification rules can achieve good levels of sensitivity, the present study indicates that their lower specificity (high false-positive rate) would therefore necessitate a greater frequency of eye examinations.

Department of Biostatistics Institute of Translational Medicine University of Liverpool Liverpool UK

Department of Eye and Vision Science Institute of Ageing and Chronic Disease University of Liverpool Liverpool UK

Department of Medical Physics and Clinical Engineering Royal Liverpool University Hospital Liverpool UK

Department of Probability and Mathematical Statistics Faculty of Mathematics and Physics Charles University Prague Czech Republic

Diabetes and Endocrinology Royal Liverpool University Hospital Liverpool UK

Gloucestershire Retinal Research Group Gloucestershire Hospitals NHS Foundation Trust Cheltenham General Hospital Cheltenham UK

St Paul's Eye Unit Royal Liverpool University Hospital Liverpool UK

Zobrazit více v PubMed

Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta‐analysis. Diabetes Care. 2009;32:2307‐2313. PubMed PMC

Scanlon PH. The English national screening programme for sight‐threatening diabetic retinopathy. J Med Screen. 2008;15:1‐4. PubMed

Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty‐five‐year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859‐1868. PubMed PMC

Javitt JC, Aiello LP. Cost‐effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124:164‐169. PubMed

ETDRS . Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796‐1806. PubMed

Savolainen EA, Lee QP. Diabetic retinopathy ‐ need and demand for photocoagulation and its cost‐effectiveness: evaluation based on services in the United Kingdom. Diabetologia. 1982;23:138‐140. PubMed

DRS . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88:583‐600. PubMed

Eleuteri A, Fisher AC, Broadbent DM, et al. Individualised variable interval risk‐based screening for sight threatening diabetic retinopathy – the Liverpool Risk Calculation Engine. Diabetologia. 2017;60(11):2174‐2182. PubMed PMC

Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost‐effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015;19(74):1‐116. PubMed PMC

Stratton IM, Aldington SJ, Farmer AJ, Scanlon PH. Personalised risk estimation for progression to sight‐threatening diabetic retinopathy: how much does clinical information add to screening data? Diabet Med. 2014;31(suppl 1):23‐24.

Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556‐564. PubMed PMC

Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: a prospective cohort study. BMJ. 2018;37:a918. PubMed PMC

Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight‐threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med. 2003;20:758‐765. PubMed

Younis N, Broadbent DM, Vora JP, Harding SP, Liverpool Diabetic Eye Study . Incidence of sight‐threatening retinopa‐ thy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195‐200. PubMed

Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156‐163. PubMed

Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high‐risk proliferative diabetic retinopathy and severe visual loss: ETDRS Report #18. Invest Ophthalmol Vis Sci. 1998;39:232‐252. PubMed

UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703‐713. PubMed PMC

Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long‐term metabolic control in type 1 diabetes mellitus: a five year follow‐up study of 442 adult patients in routine care. Diabetes Res Clin Pract. 1997;35:113‐121. PubMed

Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med. 1993;329:977‐986. PubMed

Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin‐dependent diabetes mellitus. Ophthalmology. 1993;100:1133‐1139. PubMed

Klein R, Klein BE, Moss SE, Davis MD, DeMets D. Glycosolated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864‐2871. PubMed

Diabetes Control and Complications Trial Research Group . The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin‐dependent diabetes mellitus. Arch Ophthalmol. 1995;113(1):36‐51. PubMed

Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes Care. 2004;53(11):2883‐2892. PubMed

Sampson CJ, James M, Broadbent DM, Harding SP. Stratifying the NHS Diabetic Eye Screening Programme: into the unknown? Diabet Med. 2016;33(12):1612‐1614. 10.1111/dme.13192. PubMed DOI

Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight‐threatening diabetic retinopathy. Diabetes Care. 2013;36:580‐585. PubMed PMC

UK National Screening Committee Screening for Diabetic Retinopathy . Extending diabetic eye screening intervals for people at low risk of developing sight threatening retinopathy. 2015. https://legacyscreening.phe.org.uk/policydb_download.php?doc=546. Accessed January 26, 2018.

Scottish Intercollegiate Guidelines Network (SIGN) . Management of Diabetes A National Clinical Guideline. Edinburgh, UK: Royal College of Physicians; 2010. Revised 2017. http://www.sign.ac.uk/assets/sign116.pdf. Accessed January 27, 2018.

Public Health England . NHS public health functions agreement 2017–2018. Service specification no. 22. NHS Diabetic Eye Screening Programme. 2017. https://www.england.nhs.uk/wp-content/uploads/2017/04/service-spec-22.pdf. Accessed February 22, 2018.

Hughes D, Komárek A, Bonnett L, Czanner G, García‐Fiñana M. Dynamic longitudinal discriminant analysis using multiple longitudinal markers of different types. Stat Methods Med Res. 2018;27(7):2060‐2080. PubMed PMC

Hughes D, Komárek A, Czanner G, García‐Fiñana M. Dynamic prediction using credible intervals in longitudinal discriminant analysis. Stat Med. 2017;36:3858‐3874. PubMed PMC

Plummer M. Penalized loss functions for Bayesian model comparison. Biostatistics. 2008;9:523‐539. PubMed

Komárek A, Komárková L. Capabilities of R Package mixAK for clustering based on multivariate continuous and discrete longitudinal data. J Stat Softw. 2014;59(12):1‐38. PubMed

American Diabetes Association . American Diabetes Association: standards of medical care in diabetes. Diabetes Care. 2013;36:S11‐S66. PubMed PMC

Olafsdottir E, Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10‐year experience. Br J Ophthalmol. 2007;91:1599‐1601. PubMed PMC

Aspelund T, Thornorisdottir O, Olafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia. 2011;54(10):2525‐2532. 10.1007/s00125-011-2257-7. PubMed DOI

Scanlon PH. Screening intervals for diabetic retinopathy and implications for care. Curr Diab Rep. 2017;17(10):96. PubMed PMC

Nathan DM, Bebu I, Hainsworth D, et al. Frequency of evidence‐based screening for retinopathy in Type 1 diabetes. N Engl J Med. 2017;376(16):1507‐1516. PubMed PMC

van der Heijden AA, Walraven I, van’ t Riet E, et al. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy. Diabetologia. 2014;57:1332‐1338. PubMed

Looker HC, Nyangoma SO, Cromie DT, et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia. 2013;56:1716‐1725. PubMed PMC

Cichosz SL, Johansen MD, Knudsen ST, Hansen TK, Hejlesen O. A classification model for predicting eye disease in newly diagnosed people with type 2 diabetes. Res Clin Pract. 2015;108(2):210‐215. PubMed

Mehlsen J, Erlandsen M, Poulsen PL, Bek T. Individualized optimization of the screening interval for diabetic retinopathy: a new model. Acta Ophthalmol. 2012;90:109‐114. PubMed

Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540‐2553. PubMed